Tumor Necrosis Factor Alfa Antagonists for Pediatric Immune-Mediated Diseases

Marcia L. Buck, Pharm.D., FCCP

Pediatr Pharm. 2007;13(8):1-4. 

In This Article


The TNFα antagonists offer a highly effective alternative to traditional therapies for the management of immune-mediated diseases. While now established in the treatment of rheumatoid arthritis and Crohn's disease, it is likely that these agents will play a role in many other disease states as well. Continued research is needed to optimize their use in children and further define their adverse effect profiles.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: